UPDATE: Citi Upgrades Zymeworks (ZYME) to Buy, 'Better Risk/Reward Has Emerged'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development
January 27, 2021 5:15 PM ESTActive drug with multiple confirmed responses and stable disease observed in several tumor types Differentiated safety profile with the majority of adverse events being grade 1 or 2 Expansion cohorts open and enrolling patients at 2.5 mg/kg once every three weeks Maximum tolerated dose not established, dose escalation continues in parallel
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that the Company has begun enrolling patients into the expansion cohort portion of... More
